STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum oil, which Analyst Group sees as an important growth driver in the coming year, as it distinguishes STENOCARE from competitors, providing improved, uniform and faster uptake in the blood. The product became available to patients in three countries during Q1-25, Germany, Australia, and Norway. With estimated net sales of DKK 13.7m by 2027, an applied P/S multiple of 2.3x and a discount rate of 16%, a potential present value per share of DKK 0.55 (0.64) is derived in a Base scenario.
LÄS MER
